A detailed history of Price T Rowe Associates Inc transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 298,111 shares of MCRB stock, worth $214,639. This represents 0.0% of its overall portfolio holdings.

Number of Shares
298,111
Previous 363,650 18.02%
Holding current value
$214,639
Previous $510,000 54.51%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.75 - $1.56 $49,154 - $102,240
-65,539 Reduced 18.02%
298,111 $232,000
Q4 2023

Feb 14, 2024

BUY
$0.93 - $2.15 $29,563 - $68,346
31,789 Added 9.58%
363,650 $510,000
Q3 2023

Nov 14, 2023

BUY
$2.33 - $5.07 $40,621 - $88,390
17,434 Added 5.54%
331,861 $791,000
Q2 2023

Aug 14, 2023

SELL
$4.67 - $6.55 $1.26 Million - $1.77 Million
-269,645 Reduced 46.17%
314,427 $1.51 Million
Q1 2023

May 15, 2023

BUY
$4.95 - $6.09 $7,563 - $9,305
1,528 Added 0.26%
584,072 $3.31 Million
Q4 2022

Feb 14, 2023

BUY
$5.09 - $9.05 $48,624 - $86,454
9,553 Added 1.67%
582,544 $3.26 Million
Q3 2022

Nov 14, 2022

BUY
$3.5 - $7.2 $14,987 - $30,830
4,282 Added 0.75%
572,991 $3.68 Million
Q2 2022

Aug 15, 2022

BUY
$2.7 - $7.62 $1,350 - $3,810
500 Added 0.09%
568,709 $1.95 Million
Q1 2022

May 16, 2022

BUY
$6.3 - $8.84 $48,163 - $67,581
7,645 Added 1.36%
568,209 $4.05 Million
Q4 2021

Feb 14, 2022

SELL
$6.02 - $11.43 $4.82 Million - $9.14 Million
-799,959 Reduced 58.8%
560,564 $4.67 Million
Q3 2021

Nov 15, 2021

SELL
$5.46 - $22.6 $149,145 - $617,341
-27,316 Reduced 1.97%
1,360,523 $9.47 Million
Q2 2021

Aug 16, 2021

SELL
$18.46 - $24.36 $544,625 - $718,693
-29,503 Reduced 2.08%
1,387,839 $33.1 Million
Q1 2021

May 17, 2021

SELL
$17.66 - $28.92 $8.23 Million - $13.5 Million
-465,918 Reduced 24.74%
1,417,342 $29.2 Million
Q4 2020

Feb 16, 2021

BUY
$23.25 - $37.73 $43.8 Million - $71.1 Million
1,883,260 New
1,883,260 $46.1 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $89.3M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.